Definition of the genomic make-up of triple negative HER2-low breast cancer to identify new patients who can benefit from anti-HER2 therapy
In the context of the TESEO project my main research project deals with the study of the genetic landscape of HER2-low breast carcinomas, in particular of those having a triple negative phenotype according to international guideline definition.
To accomplish the tasks of the project I am collaborating with pathologists, geneticists, surgeons and oncologists to define the details of the cohort and to coordinate the molecular analyses that can help us tease out the specific features of these breast carcinomas. I am also working with Prof. Nicola Crosetto, Visiting Professor from Karolinska Institutet (Bienko and Crosetto Laboratory for Quantitative Genome Biology, Science for Life Laboratory - Stockholm, Sweden), who is helping me set up a new technique of genome sequencing that will provide us with copy number profiles of these carcinomas with a quick turnaround time and low costs. My main goal for the translation of this project to the clinical setting would be to devise new methods to better characterize HER2-low breast carcinomas so that we reach a higher precision in oncology when medical oncologists have to decide the best treatment for these breast cancer patients.
